Subscribe     Pay Now

Iceland Project Notice - Dementia/Alzheimer Drug Attributed To Cystatin-C And Other Mutations – Precision Medicine Drug Development


Project Notice

PNR 57804
Project Name Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
Project Detail With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimer’s Disease (60% of dementia cases), potentially changing the lives of millions for the better.
Funded By European Union (EU)
Country Iceland , Northern Europe
Project Value ISK 3,571,875

Contact Information

Company Name ARCTIC THERAPEUTICS EHF
Address Brekkubaer 24 110 Reykjavik
Web Site https://cordis.europa.eu/project/id/190174464

Tell us about your Product / Services,
We will Find Tenders for you